Baillie Gifford & Co. Lowers Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Baillie Gifford & Co. cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 15,017,666 shares of the medical device company’s stock after selling 308,265 shares during the quarter. Baillie Gifford & Co.’s holdings in DexCom were worth $1,006,784,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom during the second quarter valued at $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. Crewe Advisors LLC purchased a new position in DexCom during the first quarter valued at $29,000. Riverview Trust Co lifted its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC lifted its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $70.31 on Tuesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The business’s 50-day moving average price is $69.66 and its 200 day moving average price is $93.10. The firm has a market cap of $27.46 billion, a P/E ratio of 42.10, a P/E/G ratio of 2.15 and a beta of 1.17.

Analyst Ratings Changes

Several equities analysts have issued reports on DXCM shares. Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Barclays decreased their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. JPMorgan Chase & Co. raised their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.